Lutein and Zeaxanthin
other · also known as lutein, zeaxanthin, macular carotenoids, xanthophylls
This is general information, not medical advice. Supplements can interact with medicines and health conditions. Always check with your doctor or pharmacist before starting or changing supplements.
What it is
Lutein and zeaxanthin are dietary carotenoids, yellow-orange pigments related to beta-carotene, that the body cannot synthesise and must obtain from food (leafy greens, corn, egg yolks) or supplements. They selectively accumulate in the macula of the retina, where together with a related pigment (meso-zeaxanthin) they form the macular pigment, a natural blue-light filter and antioxidant thought to protect photoreceptors from oxidative damage. Because they are almost always studied and supplemented together in a fixed ratio, this monograph treats lutein and zeaxanthin as a single combined supplement rather than two separate ingredients. The strongest evidence for a genuine clinical benefit comes from the large AREDS2 trial, which found that a lutein+zeaxanthin combination helps slow progression to advanced age-related macular degeneration (AMD) in patients who already had intermediate or worse AMD in at least one eye, and did so more safely than the beta-carotene it can replace. In healthy people without AMD, supplementation reliably raises macular pigment optical density (a biomarker of macular carotenoid status), but whether this translates into a meaningful protective or functional benefit for people with healthy eyes is not established. Marketing claims about relieving digital eye strain or screen-related visual fatigue are not well supported: the one relevant randomised trial found no improvement in self-reported eye strain, only in objective dry-eye surface measures.
Evidence-based benefits
In people with intermediate or advanced age-related macular degeneration (AMD) in at least one eye, lutein 10 mg + zeaxanthin 2 mg/day works as well as, and in direct comparisons appears to work somewhat better and more safely than, the beta-carotene it can replace in an AREDS-type formula for slowing progression to advanced AMD; the benefit is specific to people who already have AMD, not established for people with healthy eyes.
The AREDS2 trial (2013), a multicenter, randomised, double-masked, placebo-controlled trial in 4,203 participants with intermediate or advanced AMD in one eye, found that adding lutein+zeaxanthin (or omega-3 fatty acids) to the original AREDS antioxidant/mineral formula did not produce a large additional reduction in 5-year progression to advanced AMD beyond the original formula alone (29% with lutein+ zeaxanthin vs 31% without); this pre-specified primary comparison against placebo was not statistically significant (P=.12). However, a secondary, explicitly "exploratory" analysis in the same trial (AREDS2 Report No. 3, 2014) found that in a different, direct comparison, formulations containing lutein+zeaxanthin and no beta-carotene versus formulations containing beta-carotene and no lutein/zeaxanthin, the lutein+zeaxanthin formulations significantly reduced progression to advanced AMD (hazard ratio 0.82, p=0.02) and to neovascular AMD (hazard ratio 0.78, p=0.01), with the largest relative benefit (about 25%) in participants who had the lowest dietary lutein/zeaxanthin intake at baseline. Because this significant finding comes from one trial's post-hoc/exploratory secondary analysis against a different comparator rather than the primary randomised comparison or independent replication, it is graded as limited (not multiple-RCT-strength) evidence. Because beta-carotene increases lung cancer risk in smokers, lutein+zeaxanthin is nonetheless now generally preferred as the safer substitute in AREDS2-type formulas for AMD patients; this evidence does not extend to preventing AMD in people without existing disease.
- Grade B· Limited evidence[1]
Lutein/zeaxanthin supplementation dose-dependently increases macular pigment optical density (MPOD), a biomarker of macular carotenoid status, in healthy adults, though whether a given MPOD increase itself produces a meaningful visual or protective benefit in people without eye disease is not established.
A 2021 systematic review and meta-analysis of 46 studies (3,189 participants) found no significant MPOD increase at intakes below 5 mg/day of combined lutein/zeaxanthin, a pooled increase of 0.04 MPOD units at 5-20 mg/day, and 0.11 units at doses of 20 mg/day or more, indicating a dose-dependent effect. MPOD is a validated biomarker of macular carotenoid accumulation, but the review did not establish that a given MPOD increase directly translates into improved vision or disease protection in people with healthy eyes.
- Grade D· Traditional/anecdotal[1]
Marketing claims that lutein/zeaxanthin relieves digital eye strain or visual fatigue from screen use are not well supported: the one available randomised trial found no significant improvement in self-reported eye strain or attention versus placebo, though it did find improvements in objective dry-eye surface measures in heavy screen users.
A 2025 randomised, double-blind, placebo-controlled trial gave 70 adult heavy screen users (more than 6 hours/day) either 10 mg lutein + 2 mg zeaxanthin-isomers or placebo for 6 months. Compared with placebo, the supplement group showed greater improvement in objective ocular-surface measures (Schirmer tear test, tear film break-up time, photostress recovery time), but there were no significant between-group differences in self-reported visual fatigue/eye strain, computer-vision symptoms, sleep quality, or attention, the outcomes most directly relevant to a "screen fatigue" marketing claim. This is a single small trial of one branded ingredient; the finding should be read as evidence against, not for, a subjective eye-strain benefit, alongside modest support for an objective dry-eye surface effect.
Risks & contraindications
- Grade B· Limited evidence[1]
Lutein and zeaxanthin supplementation is well tolerated in clinical trials at studied doses, with no evidence of serious toxicity; the main recognised effect at high intakes is carotenodermia, a harmless, reversible yellow-orange skin discolouration.
The AREDS2 trial followed 4,203 participants for a median of 5 years on lutein 10 mg + zeaxanthin 2 mg/day (among other antioxidants and minerals) without identifying safety signals specific to the lutein/zeaxanthin arms. Large randomised trials and meta-analyses of lutein/zeaxanthin supplementation consistently report no serious adverse events, with skin yellowing (carotenodermia), a harmless, dose-dependent, and reversible cosmetic effect from carotenoid accumulation in skin, being the most commonly noted change at higher intakes.
Dosage & how to take it
- Lutein and zeaxanthin (combined): 10–20 mg/day, any time of day, with food. The most-studied and AREDS2-validated dose is 10 mg lutein + 2 mg zeaxanthin/day (a combined 12 mg, roughly a 5:1 ratio); this 10-20 mg combined range also covers other trials that used higher lutein- dominant combinations for macular pigment optical density. Always take with a meal containing some fat, since these are fat-soluble carotenoids and absorption is significantly reduced on an empty stomach. Do not assume a higher dose or a different lutein:zeaxanthin ratio than what was studied will produce a proportionally larger benefit.
Interactions
No interactions in our database yet. We check against a limited set of medications. Absence of a warning is not evidence of safety.
Our medication coverage is not exhaustive. Absence of a warning here is not evidence of safety. Always confirm with your pharmacist.
Where to buy
Checking current prices…